• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Emergency

Updated review confirms efficacy and safety of most standard treatments for latent tuberculosis infection

byCaitlyn HuiandDeepti Shroff Karhade
August 3, 2017
in Emergency, Infectious Disease, Public Health
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Results of a meta-analysis confirm evidence of efficacy and safety of 6-month isoniazid monotherapy and rifampicin monotherapy for latent tuberculosis infection treatment.

2. Combination therapies with 3 to 4 months of isoniazid and rifampicin were also shown to be safe and effective for latent tuberculosis infection treatment.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Tuberculosis (TB) is one of several priority global infectious diseases, and treatment of latent tuberculosis infection (LTBI) is a highly important component of TB control. The purpose of this systematic review and meta-analysis was to evaluate the comparative efficacy and harms of LTBI treatment regimens aimed at preventing active TB. The analysis focused on treatments used both for adults and children. Generally, the updated network meta-analysis suggested that most standard treatments for LTBI are safe and effective. This study has several limitations. First, there was a paucity of evidence regarding hepatotoxicity outcomes amongst trials. Additionally, there was a high risk of bias to many of the underlying studies, which were small in sample size or used nonstandard end point definitions. Quality and reporting standards also formed further limitations.

Click to read the study, published in the Annals of Internal Medicine

Relevant Reading: Diagnosis and Treatment of Latent Tuberculosis Infection

In-Depth [meta-analysis]: The authors of this study conducted an updated network meta-analysis. Articles were retrieved from PubMed, Embase, and Web of Science from indexing to 8 May 2017, in addition to clinical trial registries and conference abstracts. Inclusion criteria consisted of randomized controlled trials that evaluated human LTBI treatments and recorded at least 1 or 2 endpoints—hepatotoxicity and/or prevention of active TB. Two independent reviewers extracted data. In total, the network meta-analysis included 8 new studies and 53 previously identified studies. In general, safety and efficacy was observed for most standard treatments of LTBI. For example, isoniazid regimens of 6 months (odds ratio [OR], 0.65; 95% credible interval [Crl], 0.50 to 0.83) or 12 to 72 months (OR, 0.50; Crl, 0.41 to 0.62) were efficacious compared to placebo. Similar findings were observed for rifampicin-only regimens, rifampicin-isoniazid regimens of 3 to 4 months, rifampicin-isoniazid-pyrazinamide regimens, and rifampicin-pyrazinamide regimens.

RELATED REPORTS

#VisualAbstract: Non-severe tuberculosis in children can be treated with a shorter 4-month regimen instead of 6-month regimen

Non-severe tuberculosis in children can be treated with a shorter 4-month regimen

#VisualAbstract: Rifapentine-moxifloxacin noninferior to standard of care treatment for pulmonary tuberculosis

Image: PD

©2017 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: tuberculosis
Previous Post

Over one-third of U.S. adults used a prescription opioid in 2015

Next Post

Despite adverse events, corticosteroids may benefit patients with IgA nephropathy

RelatedReports

#VisualAbstract: COVID-19 vaccines provided durable protection from COVID-19, but their effectiveness waned over time in North Carolina
StudyGraphics

#VisualAbstract: Non-severe tuberculosis in children can be treated with a shorter 4-month regimen instead of 6-month regimen

April 13, 2022
Updated review confirms efficacy and safety of most standard treatments for latent tuberculosis infection
Chronic Disease

Non-severe tuberculosis in children can be treated with a shorter 4-month regimen

March 16, 2022
#VisualAbstract: Rifapentine-moxifloxacin noninferior to standard of care treatment for pulmonary tuberculosis
StudyGraphics

#VisualAbstract: Rifapentine-moxifloxacin noninferior to standard of care treatment for pulmonary tuberculosis

May 18, 2021
Updated review confirms efficacy and safety of most standard treatments for latent tuberculosis infection
Chronic Disease

Rifapentine-moxifloxacin noninferior to standard of care treatment for pulmonary tuberculosis

May 10, 2021
Next Post
Being overweight and obese associated with increased incidence of chronic kidney disease

Despite adverse events, corticosteroids may benefit patients with IgA nephropathy

Intensive rehabilitation not superior to traditional therapy for arm function after stroke

First-line use of contact aspiration not superior to stent retriever for acute ischemic stroke

Features predicting treatment failure in acute otitis media

Features predicting treatment failure in acute otitis media

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Cognitive behavioral therapy efficacious for treatment of comorbid posttraumatic headache and posttraumatic stress disorder symptoms among US veterans
  • Sickle cell trait associated with preexisting kidney comorbidities and increased COVID-19 mortality
  • Adding atezolizumab to standard of care treatment for human epidermal growth factor receptor 2 (HER2) positive early breast cancer does not improve pathologic response outcomes
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.